From Washington Post:
"Researchers at the Agriculture Department and the Department of Health and Human Services reported that testing of hundreds of livestock and retail meats turned up the same colistin-resistant bacteria in a sample from a pig intestine in the United States."
I agree, I want to buy more but the case with the multi-resistant bacteria is alarming and maybe skyrockets AKAO next week.
Dr. Ian Friedland, M.D. is Chief Medical Officer served as Achaogen Chief Medical Officer since July 2014. Dr. Friedland joined Achaogen from Cubist Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, where he has served as Vice President, Clinical Research since joining Cubist in December 2009. From January 2009 to December 2009, Dr. Friedland served as Chief Medical Officer at Calixa Therapeutics, Inc., a pharmaceutical company acquired by Cubist in December 2009.
So, Dr. Friedland was in Calixa for about a year, leading the clinical trials for Zerbaxa (formely known as CXA-201) which was at Phase II when Cubist acquired the company.
Dr. Friedland continue his work in Cubist until 2014, when Zerbaxa was ready: The drug was approved under the Generating Antibiotic Incentives Now (GAIN) Act and is designated as a Qualified Infectious Disease Product (QIDP) by the FDA.
Dr. Friedland SUCCEED with Zerbaxa, and then has joined Achaogen and leads to the recearch about PLAZOMICIN, which is in Phase III.
Sentiment: Strong Buy
I suggest to read George Kesarios articles in SA, he predicted the turn around and he explains why even $10 is possible in 2016.
YO trades at C$1/MMboe (!!) next to KEL, TET & others.
YO now has Zero Debt after paying down the bank debt and the debentures thanks to the proceeds from the recent Duvernay sale of C$50 million.
YO has 12.9 MMBoe of 2P Reserves based on Jan 2016 pricing, see presentation.
After paying the debentures, YO now has about C$5 million working capital (surplus).
YO's Enterprise Value at C$0.29 per share is C$13 million.
So YO now trades just C$1/MMboe of 2P Reserves at C$0.29 per share.
Do you really believe that YO will keep trading at just C$1/MMboe of 2P Reserves next to other producers..?
All the recent Montney deals (ORLEN - KCK, CIOC - Riverstone Seneca, Black Swan - Carmel Bay, Canamax - Edge Fund) take place at about C$10/MMboe and higher.
Mark my words, YO will be acquired by year end by its neighbors, take a look at them. All cash or all-stock deal.
Sentiment: Strong Buy